Heron Therapeutics Inc. (HRTX) Shares Down 2.4%

heron-therapeutics-inc-hrtx-shares-down-24.png

Heron Therapeutics Inc. (NASDAQ:HRTX)’s share price traded down 2.4% during mid-day trading on Thursday . The stock traded as low as $18.70 and last traded at $19.15, with a volume of 248,114 shares. The stock had previously closed at $19.63.
Several equities analysts have recently issued reports on the company. Jefferies Group reiterated a “buy” rating and set a $46.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, July 27th. Cantor Fitzgerald reiterated a “buy” rating and set a $38.00 price objective on shares of Heron Therapeutics in a research report on Tuesday, August 9th. Leerink Swann set a $33.00 price objective on Heron Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 11th. Cowen and Company reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Saturday, July 9th. Finally, Brean Capital reiterated a “buy” rating and set a $55.00 price objective on shares of Heron Therapeutics in a research report on Saturday, August 13th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $47.70.
The company’s 50 day moving average is $19.19 and its 200-day moving average is $18.86.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/15/heron-therapeutics-inc-hrtx-shares-down-2-4.html

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Monday, August 8th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.96) by $0.21. Analysts forecast that Heron Therapeutics Inc. will post ($4.43) earnings per share for the current fiscal year.
In related news, insider Robert Rosen sold 100,000 shares of Heron Therapeutics stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the completion of the sale, the insider now owns 102,640 shares of the company’s stock, valued at approximately $2,391,512. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 20.31% of the company’s stock.
A number of hedge funds have recently modified their holdings of HRTX. Schwab Charles Investment Management Inc. boosted its stake in shares of Heron Therapeutics by 8.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 111,768 shares of the biotechnology company’s stock valued at $2,018,000 after buying an additional 8,772 shares during the period. Metropolitan Life Insurance Co. NY boosted its stake in shares of Heron Therapeutics by 25.4% in the second quarter. Metropolitan Life Insurance Co. NY now owns 26,014 shares of the biotechnology company’s stock valued at $470,000 after buying an additional 5,268 shares during the period. Panagora Asset Management Inc. boosted its stake in shares of Heron Therapeutics by 6.5% in the second quarter. Panagora Asset Management Inc. now owns 261,298 shares of the biotechnology company’s stock valued at $4,716,000 after buying an additional 15,906 shares during the period. Barclays PLC boosted its stake in shares of Heron Therapeutics by 255.0% in the second quarter. Barclays PLC now owns 30,905 shares of the biotechnology company’s stock valued at $558,000 after buying an additional 22,199 shares during the period. Finally, Parametric Portfolio Associates LLC acquired a new stake in shares of Heron Therapeutics during the second quarter valued at $213,000.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Receive News & Ratings for Heron Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Heron Therapeutics Inc. (HRTX) Shares Down 2.4%"

Leave a comment

Your email address will not be published.

*